Introduction: Clostridium difficile (C. difficile) is a major nosocomial infectious agent in hospitals. Previous studies have addressed the high proportion of infection episodes that are overlooked in health care facilities.
Objective: the main aim of this study was to characterize C. difficile clinical cases that occurred in a secondary care hospital during a five-month period.
Material And Methods: for this purpose, a total of 137 stool samples from the same number of patients with diarrhea were analyzed for the presence of C. difficile by culture techniques. An enzyme immunoassay (EIA) test for the detection of C. difficile and its toxins was also used in 50 cases (36.5%) for diagnostic purposes.
Results: a total of 14 (10.2%) C. difficile isolates were obtained, of which nine (64.3%) were toxigenic. A mean incidence of 3.2 episodes of C. difficile infections (CDI) per 10,000 patients-days was estimated for the study period. Around 56% of the CDI cases were determined as hospital-acquired, whereas 44% originated in the community. Among these, only two episodes (22.2%) were detected in the hospital by the EIA test, which indicated that the hospital CDI detection protocol needed to be revised. One unusual C. difficile isolate was negative for all toxin genes examined and also for the non-toxigenic strain assay, which highlights the need to perform genome sequencing to study its pathogenicity locus insertion site organization. A stable metronidazole-resistant C. difficile strain and three strains showing multidrug resistance were detected in this study, suggesting that C. difficile antimicrobial susceptibility surveillance programs should be established in this health-care facility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2018.5288/2017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Outcomes and Infection Risk in Medical, Surgical, and Trauma Intensive Care Patients with Alcohol Use Disorder.
Surg Infect (Larchmt)
January 2025
Essentia Institute of Rural Health, Duluth, Minnesota, USA.
Alcohol is the most frequently abused drug in the United States, and alcohol use disorder (AUD) is a common comorbidity in intensive care units (ICUs). We performed a retrospective chart review of patients admitted to an ICU between January 2017 and March 2019 at a tertiary hospital serving a large rural population. Patients with diagnoses of AUDs were included.
View Article and Find Full Text PDFImpact of adjunct bezlotoxumab for preventing infection recurrence in patients post - hematopoietic stem cell transplantation.
J Oncol Pharm Pract
January 2025
Department of Pharmacy, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA.
Background: Patients post hematopoietic stem cell transplant (HSCT) are highly susceptible to infection (CDI). Exposure to antibiotic treatment, chemotherapeutic disruption to bacterial microbiome, immunosuppressive therapy, and prolonged hospitalizations synergistically contribute to the risk of CDI and its recurrence. The purpose of this study is to assess if the adjunctive administration of bezlotoxumab decreases the rate of recurrent CDI in patients post-HSCT.
View Article and Find Full Text PDFWhole genome sequencing characterization of Clostridioides difficile from Bulgaria during the COVID-19 pandemic.
Diagn Microbiol Infect Dis
January 2025
National Reference Laboratory of Control and Monitoring of Antibiotic Resistance (NRL-CMAR), Department Microbiology, National Center of Infectious and Parasitic Diseases (NCIPD), 26 Yanko Sakazov Blvd., Sofia, Bulgaria.
Increased incidence of Clostridioides difficile infections were documented in Bulgarian hospitals during COVID-19. WGS was performed on 39 isolates from seven hospitals during 2015-2022. Antimicrobial resistance and toxin genes were inferred from genomes.
View Article and Find Full Text PDFSafety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS.
Inflamm Bowel Dis
January 2025
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Background: Fecal microbiota, live-jslm (RBL; REBYOTA®), is the first single-dose, broad consortia, microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults following standard-of-care antimicrobials. Inflammatory bowel disease (IBD) is a common risk factor for rCDI, yet patients with IBD are often excluded from prospective trials. This subgroup analysis of PUNCH CD3-OLS (NCT03931941) evaluated the safety and efficacy of RBL in participants with rCDI and IBD.
View Article and Find Full Text PDFCan Gut Microbiota Analysis Reveal Infection? Evidence from an Italian Cohort at Disease Onset.
Microorganisms
December 2024
Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
A diverse and well-functioning gut microbiota normally serves as a protective shield against the invasion of harmful bacteria or the proliferation of opportunistic pathogens. infection (CDI) is predominantly associated with the overuse of antibiotics, resulting in a significant alteration in the gut's microbial balance. Unfortunately, the lack of global standardization does not allow for the identification of a set of biomarkers associated with the onset and progression of this disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!